A detailed history of Salomon & Ludwin, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Salomon & Ludwin, LLC holds 7,427 shares of ABBV stock, worth $1.23 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares
7,427
Previous 7,419 0.11%
Holding current value
$1.23 Million
Previous $1.15 Million 17.67%
% of portfolio
0.12%
Previous 0.11%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 02, 2024

BUY
$159.82 - $182.1 $1,278 - $1,456
8 Added 0.11%
7,427 $1.35 Million
Q3 2023

Nov 13, 2023

BUY
$133.59 - $154.65 $7,881 - $9,124
59 Added 0.8%
7,419 $1.11 Million
Q2 2023

Jul 21, 2023

SELL
$132.51 - $164.9 $1,325 - $1,649
-10 Reduced 0.14%
7,360 $991,000
Q4 2022

Feb 08, 2023

BUY
$138.31 - $165.87 $1,106 - $1,326
8 Added 0.11%
7,370 $1.19 Million
Q3 2022

Nov 03, 2022

BUY
$134.21 - $153.93 $402,495 - $461,636
2,999 Added 68.74%
7,362 $988,000
Q2 2022

Aug 03, 2022

BUY
$137.62 - $174.96 $33,716 - $42,865
245 Added 5.95%
4,363 $668,000
Q1 2022

May 06, 2022

BUY
$131.98 - $163.75 $21,248 - $26,363
161 Added 4.07%
4,118 $668,000
Q4 2021

Feb 04, 2022

BUY
$107.43 - $135.93 $425,100 - $537,875
3,957 New
3,957 $536,000
Q2 2020

Jul 17, 2020

SELL
$73.37 - $98.18 $19,663 - $26,312
-268 Closed
0 $0
Q1 2020

Apr 03, 2020

SELL
$64.5 - $97.79 $61,210 - $92,802
-949 Reduced 77.98%
268 $20,000
Q4 2019

Feb 07, 2020

BUY
$72.13 - $90.25 $57,704 - $72,200
800 Added 191.85%
1,217 $108,000
Q2 2019

Aug 20, 2019

SELL
$65.7 - $83.98 $2,233 - $2,855
-34 Reduced 7.54%
417 $30,000
Q1 2019

May 14, 2019

BUY
$77.14 - $90.79 $2,622 - $3,086
34 Added 8.15%
451 $0
Q4 2018

Feb 13, 2019

BUY
$77.85 - $96.01 $32,463 - $40,036
417 New
417 $38,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $293B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Salomon & Ludwin, LLC Portfolio

Follow Salomon & Ludwin, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Salomon & Ludwin, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Salomon & Ludwin, LLC with notifications on news.